Business & M&A
The latest in business & m&a for medical-aesthetics practice owners.
Business & M&A
Evolus posts Q3 loss of $0.09, revenue tops estimates
Evolus reported a wider-than-expected loss on $77.95 million in revenue for the September 2026 quarter, and the EPS miss matters less than the top line.
Business & M&A
Hugel Signs Half of Target U.S. Accounts Post-Switch
Four months into direct selling of Letybo, Hugel reports more than half its strategic accounts in activation, while third-quarter operating profit fell 61.8%.
Business & M&A
Maple Grove med spa adds PA-led hormone and weight program
Remedy Medical Aesthetics & Wellness hired a board-certified PA to run a wellness track covering BHRT, GLP-1 weight management and peptides.
Business & M&A
Sofwave Q3 revenue up 35% to $28.5M; China nod
Usage fees grew 60% in the quarter, and the company now has an NMPA approval for mainland China.
Business & M&A
Evolus Q3 revenue up 13%, fourth straight positive EBITDA quarter
Evolus says toxin and hyaluronic acid sales both grew in the third quarter, and it is reaffirming 2026 guidance while it adds a Profhilo partnership and a hair-growth option.
Business & M&A
Sofwave names Optimedic main distributor in Spain
The ultrasound maker picks a Spanish distributor to reach more clinics, and the document leaves its regulatory details and terms unstated.
Business & M&A
Galderma nine-month sales hit $4.77B, guidance raised
Galderma reported record first-nine-month 2026 net sales of 4,765 million USD, lifted its full-year growth guidance, and tied the lift to a $1.5 billion ZO Skin Health purchase.
Business & M&A
AbbVie director Jennifer Davis resigns to lead Align
AbbVie's board loses Jennifer L. Davis, a Class II director, effective November 2, 2026, after she took the CEO job at Align Technology.
Business & M&A
AbbVie's Aesthetics Revenue Slips as Botox Cosmetic Gains
Allergan Aesthetics posted a 1.8 percent operational decline in Q3 2026, with Botox Cosmetic up 4.1 percent but Juvederm down 11.8 percent.
Business & M&A
Establishment Labs posts first positive cash quarter
The breast device maker hit $72 million in Q3 revenue, up 34%, with U.S. sales nearly doubling and the minimally invasive platform accelerating.
Business & M&A
Bausch Health raises 2026 guidance on 14 straight quarters of growth
The parent of Solta Medical posted 10% revenue growth in Q3 and hit $1 billion in quarterly adjusted EBITDA for the first time, excluding its eye-care unit.
Business & M&A
Steel Partners sets October 30 deadline on $16.75 InMode bid
The activist investor says InMode's board has refused to engage in good faith and breached fiduciary duties by conditioning diligence on dismissal of shareholder claims.
Business & M&A
SkinHealth Systems executes 1-for-20 reverse split
The HydraFacial parent company consolidated shares to meet Nasdaq's minimum bid price rule after stock fell below $1.
Business & M&A
Galderma buys ZO Skin Health for $1.5 billion
The Swiss dermatology company acquires the physician-dispensed skincare brand to expand its portfolio alongside Cetaphil and Alastin.
Business & M&A
Sisram Medical to repurchase up to 1% of shares
The Hong Kong-listed aesthetic-device maker announced a buyback plan as injectables revenue surged 54% in the first half of 2026.
Business & M&A
Henry Schein names ITT CFO Emmanuel Caprais as new finance chief
Emmanuel Caprais, who led ITT's financial operations for six years, takes over from Ronald South on November 4, 2026.
Business & M&A
Hugel chases 1 trillion won in three years
The Korean aesthetic medicine company is licensing outside products and shifting to direct sales in the U.S. to hit its revenue target.
Business & M&A
AbbVie takes $216M charge on Q3 deals, cuts earnings
AbbVie reported acquired IPR&D and milestones expenses of $216 million in the third quarter, reducing full-year earnings guidance by 11 cents per share.
Business & M&A
AbbVie Files Material Event: Botox/Juvéderm Pricing Shift
Allergan Aesthetics signals a move that will ripple through every injector's margin sheet.
Business & M&A
AbbVie Files Material Event on Allergan Aesthetics
SEC filing signals pricing or rebate changes affecting Botox and Juvéderm margins.
Business & M&A
Rejuran Maker PharmaResearch Acquires Cosmetic Group
South Korean injectable manufacturer expands portfolio through acquisition.
Business & M&A
AbbVie Files Material Event—Allē Rebate Terms Shifting
Botox and Juvéderm loyalty program changes signal margin pressure across the injector base.
Business & M&A
Evolus Files Material Event—Jeuveau Pricing Escalates
Aggressive Evolus Rewards program targeting medspas signals toxin price wars are live.
Business & M&A
Evolus Files Material Event—Jeuveau Pricing Shift Ahead
Evolus signals a strategic move tied to Jeuveau and its loyalty program, likely reshaping toxin economics for practices.
Business & M&A
AbbVie Files Material Event—Botox/Juvéderm Pricing Shift Ahead
SEC 8-K signals Allergan Aesthetics is making moves on Allē loyalty and rebate structure—expect margin pressure across the board.
Business & M&A
Hugel Aesthetics Launches Direct Sales Force for Letybo, Expands US Footprint
Korean toxin maker builds commercial infrastructure with new K-TOX campaign targeting US market share.
Business & M&A
Court Bid Filed to Pause InMode Takeover Review — Shareholder Litigation Clouds Steel Partners Offer
Legal challenge to InMode's acquisition process introduces execution risk and potential delays to the Steel Partners deal.
Business & M&A
Steel Partners Bids $16.75/Share for InMode — What a Takeout Means for Device Economics
Private-equity firm Steel Partners makes unsolicited $16.75-per-share cash offer for InMode, signaling PE appetite for consolidated RF and energy-device platforms.
Business & M&A
Sisram Medical Restructures DAXXIFY China Deal With Fosun Unit — Supply Chain Complexity Deepens
A revamped distribution arrangement for Daxxify in China reflects ongoing supply and regulatory challenges in the world's second-largest aesthetics market.
Business & M&A
Evolus Files Material Event on Jeuveau Loyalty Program — Pricing and Rebate Moves Signal Market Pressure
Evolus Rewards program changes suggest competitive response to AbbVie and Galderma toxin pricing.
Business & M&A
InMode Receives Unsolicited Takeover Offer — Consolidation Pressure Mounts in Energy-Device Space
PE or strategic buyer circles InMode; device M&A cycle accelerates.
Business & M&A
AbbVie Files Material Event on Allergan Aesthetics — Pricing or Rebate Move Likely Incoming
SEC 8-K signals potential changes to Botox/Juvéderm economics; monitor Allē terms closely.
Business & M&A
InMode Receives Unsolicited Buyout Proposal at $16.20 per Share — M&A Signals Consolidation Pressure
CEO-led group bids for InMode; signals continued PE and strategic interest in energy-device consolidation.
Business & M&A
Med Spa Valuation and Exit Basics: What Makes a Practice Worth Buying
Whether you ever sell or not, understanding what makes a practice valuable to a buyer is a useful lens — because the things that raise your value are mostly the things that make you well-run.
Business & M&A
AbbVie Files Multiple Material Events — Allergan Aesthetics Pricing or Rebate Moves Likely Ahead
Three SEC 8-K filings from AbbVie signal material changes to Allergan Aesthetics' business; Allē loyalty terms may be in flux.
Business & M&A
Evolus Files Multiple Material Events — Jeuveau Competitive Pricing Strategy in Motion
Evolus has filed three SEC 8-Ks; the company is likely adjusting Jeuveau pricing or Evolus Rewards rebate terms to capture market share from Allergan.
Business & M&A
Medspa Franchise vs Independent Practice: Cost, Control, and Unit Economics
Franchises offer turnkey systems and brand leverage; independents keep margin and autonomy. Here's what the real economics look like.
Business & M&A
Should Your Medspa Have a Membership Program? Models, Metrics, and Revenue Impact
Membership programs convert one-time buyers into predictable recurring revenue—but only if you structure them right. Here's what the math actually shows.
Business & M&A
How to Market a Medspa: High-Converting Channels and Real Unit Economics
The channels that drive patient acquisition, retention, and referral for independent medspas—with the metrics that matter to your P&L.
Business & M&A
How Much Revenue Can One MedSpa Treatment Room Generate?
The math on treatment-room revenue depends on utilization rate, service mix, and pricing—here's how to model your own.
Business & M&A
How Much Does It Cost to Open a Medspa? Real Buildout, Device, and Staffing Numbers
A breakdown of the actual capital required: facility, equipment, licensing, staff, and working capital for a standalone aesthetic practice.
Business & M&A
Boulevard vs Aesthetic Record vs PatientNow: Which Medspa Software Fits Your Practice
Three leading platforms dominate medspa software. Here's how they differ in pricing, features, and which practices they actually serve best.
Business & M&A
What It Takes to Open a Medical Spa: Licensing, Medical Director, Ownership, and Capital Requirements
The regulatory and financial foundation for launching a medspa depends on state law, medical director oversight, and whether you're a clinician or investor.
Business & M&A
How to Price Lip Filler at Your MedSpa: Cost Inputs, Market Rates, and Packaging Strategy
Build a defensible lip filler pricing model by understanding COGS, regional demand, and whether to sell by syringe, unit, or package.
Business & M&A
Medspa Profit Margins: What's Normal by Service Line
Gross margins for injectables, laser, and energy devices vary widely—here's what healthy medspas actually achieve and why.
Business & M&A
Botox Cost Per Unit and Profit Margin: The Real Economics for Medspa Owners
Understand wholesale acquisition costs, retail pricing benchmarks, and how rebate programs affect your bottom line.
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
The free Inside MedSpa brief · no card · unsubscribe anytime. Privacy.